Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Hinova Licenses Oral VAV1 Molecular Glue Degrader HP570 to Evommune in Up to USD 1.1 Billion Deal – Days After FDA IND Clearance for Rheumatoid Arthritis
CompanyDeals

Hinova Licenses Oral VAV1 Molecular Glue Degrader HP570 to Evommune in Up to USD 1.1 Billion Deal – Days After FDA IND Clearance for Rheumatoid Arthritis

Hinova Pharmaceuticals Inc. (SHA: 688302) announced that its self‑developed investigational drug HP570 received formal Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the treatment…

Merck Launches Phase 3 ENHANCE‑3 Trial of OHTUVAYRE (Ensifentrine) – Targeting COPD Exacerbation Prevention

Merck Launches Phase 3 ENHANCE‑3 Trial of OHTUVAYRE (Ensifentrine) – Targeting COPD Exacerbation Prevention

Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken

Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Drug

InnoCare Pharma’s BCL2 Inhibitor ICP-248 Accepted for NMPA Review

CompanyDeals

Shenzhen TargetRx Raises Hundreds of Millions in Series B Financing for Drug Development

CompanyDrug

Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA

CompanyDrug

InnoCare Pharma’s ICP-490 Receives NMPA Approval for Hematological Malignancies

CompanyDrug

PersonGen BioTherapeutics’ TAA06 Receives Clinical Trial Approval for B7-H3 CAR-T Therapy

CompanyDrug

Akeso Biopharma’s Cadonilimab Achieves National Delivery in China

CompanyDrug

Junshi Biosciences Receives FDA Approval for PI3K-α Inhibitor RP903 in Breast Cancer Study

Policy / Regulatory

NHC Releases Technical Guidelines for Drug Clinical Evaluation

Show More